688089 Stock Overview
Cabio Biotech (Wuhan) Co., Ltd. develops, produces, and markets arachidonic and docosahexaenoic acids, and beta-carotene for domestic and foreign infant formula, and healthy food manufacturers.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Cabio Biotech (Wuhan) Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥19.65 |
| 52 Week High | CN¥23.50 |
| 52 Week Low | CN¥9.98 |
| Beta | 0.58 |
| 1 Month Change | 32.15% |
| 3 Month Change | 80.77% |
| 1 Year Change | -12.08% |
| 3 Year Change | -31.55% |
| 5 Year Change | n/a |
| Change since IPO | -40.42% |
Recent News & Updates
Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected
May 06
Cabio Biotech (Wuhan)'s (SHSE:688089) Promising Earnings May Rest On Soft Foundations
May 03Recent updates
Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected
May 06Cabio Biotech (Wuhan)'s (SHSE:688089) Promising Earnings May Rest On Soft Foundations
May 03The Market Lifts Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) Shares 27% But It Can Do More
Mar 21Shareholder Returns
| 688089 | CN Chemicals | CN Market | |
|---|---|---|---|
| 7D | 34.1% | 2.3% | 1.2% |
| 1Y | -12.1% | -16.6% | -12.6% |
Return vs Industry: 688089 exceeded the CN Chemicals industry which returned -16.6% over the past year.
Return vs Market: 688089 matched the CN Market which returned -12.6% over the past year.
Price Volatility
| 688089 volatility | |
|---|---|
| 688089 Average Weekly Movement | 10.4% |
| Chemicals Industry Average Movement | 8.2% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CN Market | 12.1% |
| 10% least volatile stocks in CN Market | 5.0% |
Stable Share Price: 688089's share price has been volatile over the past 3 months.
Volatility Over Time: 688089's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 494 | Dewei Yi | www.cabio.cn |
Cabio Biotech (Wuhan) Co., Ltd. develops, produces, and markets arachidonic and docosahexaenoic acids, and beta-carotene for domestic and foreign infant formula, and healthy food manufacturers. Its products are used in infant formula food, health food, dietary supplements, and other fields for special medical purposes, pet nutrition food, economic animal feed, personal care and cosmetics, and other fields. The company was founded in 1999 and is based in Wuhan, the People’s Republic of China.
Cabio Biotech (Wuhan) Co., Ltd. Fundamentals Summary
| 688089 fundamental statistics | |
|---|---|
| Market cap | CN¥3.31b |
| Earnings (TTM) | CN¥101.38m |
| Revenue (TTM) | CN¥473.06m |
32.6x
P/E Ratio7.0x
P/S RatioIs 688089 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688089 income statement (TTM) | |
|---|---|
| Revenue | CN¥473.06m |
| Cost of Revenue | CN¥271.18m |
| Gross Profit | CN¥201.88m |
| Other Expenses | CN¥100.50m |
| Earnings | CN¥101.38m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.60 |
| Gross Margin | 42.68% |
| Net Profit Margin | 21.43% |
| Debt/Equity Ratio | 0.8% |
How did 688089 perform over the long term?
See historical performance and comparison